BACKGROUND: We tried to identify prostate-specific antigen (PSA)-derived epitopes immunogenic in HLA-A24+ prostate cancer patients. METHODS: Peripheral blood mononuclear cells (PBMCs) were in vitro stimulated with each of four different PSA peptides carrying the HLA-A24 binding motif, and their HLA-A24-restricted anti-tumor responses were examined using a parental HLA-A24-negative prostate cancer cell line (PC93) and its HLA-A24-expressing transfectant line (PC93-A24). Serum levels of immunoglobulin G (IgG) against PSA peptides were measured by enzyme-linked immunosorbent assay (ELISA). RESULTS: PBMCs, which were in vitro stimulated with either the PSA(152-160) or PSA(248-257) peptide, showed higher levels of IFN-gamma production and cytotoxicity against the PC93-A24 than against the PC93. IgG against the PSA(248-257) peptide was detected in half of the prostate cancer patients tested. CONCLUSIONS: The PSA(152-160) and PSA(248-257) peptides could be appropriate target molecules in use for specific immunotherapy of HLA-A24+ prostate cancer patients. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND: We tried to identify prostate-specific antigen (PSA)-derived epitopes immunogenic in HLA-A24+ prostate cancerpatients. METHODS: Peripheral blood mononuclear cells (PBMCs) were in vitro stimulated with each of four different PSA peptides carrying the HLA-A24 binding motif, and their HLA-A24-restricted anti-tumor responses were examined using a parental HLA-A24-negative prostate cancer cell line (PC93) and its HLA-A24-expressing transfectant line (PC93-A24). Serum levels of immunoglobulin G (IgG) against PSA peptides were measured by enzyme-linked immunosorbent assay (ELISA). RESULTS: PBMCs, which were in vitro stimulated with either the PSA(152-160) or PSA(248-257) peptide, showed higher levels of IFN-gamma production and cytotoxicity against the PC93-A24 than against the PC93. IgG against the PSA(248-257) peptide was detected in half of the prostate cancerpatients tested. CONCLUSIONS: The PSA(152-160) and PSA(248-257) peptides could be appropriate target molecules in use for specific immunotherapy of HLA-A24+ prostate cancerpatients. Copyright 2003 Wiley-Liss, Inc.
Authors: Ioannis F Voutsas; Eleftheria A Anastasopoulou; Sonia A Perez; Constantin N Baxevanis; Panagiotis Tzonis; Michael Papamichail Journal: J Immunother Cancer Date: 2016-11-15 Impact factor: 13.751
Authors: Adeline N Boettcher; Ahmed Usman; Alicia Morgans; David J VanderWeele; Jeffrey Sosman; Jennifer D Wu Journal: Front Oncol Date: 2019-09-11 Impact factor: 6.244
Authors: A Yao; M Harada; S Matsueda; Y Ishihara; H Shomura; M Noguchi; K Matsuoka; I Hara; S Kamidono; K Itoh Journal: Br J Cancer Date: 2004-07-19 Impact factor: 7.640